Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients.
Dennis M, Thomas IF, Ariti C, Upton L, Burnett AK, Gilkes A, Radia R, Hemmaway C, Mehta P, Knapper S, Clark RE, Copland M, Russell N, Hills RK.
Dennis M, et al. Among authors: clark re.
Blood Adv. 2021 Dec 28;5(24):5621-5625. doi: 10.1182/bloodadvances.2021005038.
Blood Adv. 2021.
PMID: 34597366
Free PMC article.
Clinical Trial.